Biomarkers in nasal exhaled breath
A method of diagnosing or assessing risk of a tauopathy in a person is disclosed. The method may comprise collecting a nasal sample of exhaled breath from the person's nose, analyzing the nasal sample to detect the presence of tau protein in the sample, and determining the concentration of tau protein in the nasal sample, wherein the tau protein concentration in the nasal sample indicates susceptibility to the tauopathy.
1. A method, comprising:
collecting a nasal sample of exhaled breath from a person's nose using a nasal breath collection device;
analyzing the nasal sample of exhaled breath from the person's nose to detect and measure a concentration of the at least one neural biomarker in the nasal sample of exhaled breath from the person's nose;
collecting a mouth sample of exhaled breath from a person's mouth using a collection device;
analyzing the mouth sample to detect a concentration of the at least one biomarker in the mouth sample; and
subtracting the concentration of the at least one biomarker in the mouth sample of exhaled breath from the person's mouth from the concentration of the at least one biomarker in the nasal sample of exhaled breath from the person's nose to determine an adjusted biomarker concentration.
2. The method of claim 1 , further comprising correlating the adjusted biomarker concentration with at least one medical condition.
3. The method of claim 1 , further comprising condensing the nasal sample of exhaled breath from the person's nose and detecting and measuring the concentration of the at least one neural biomarker in the condensed sample of exhaled nasal breath from the person's nose.
4. The method of claim 1 , further comprising vaporizing the nasal sample of exhaled breath from the person's nose and detecting and measuring the concentration of the at least one neural biomarker in the vaporized sample of exhaled nasal breath from the person's nose.
5. The method of claim 2 , wherein the at least one medical condition is dementia.
6. The method of claim 2 , wherein the at least one medical condition is Alzheimer's disease.
7. A method of diagnosing or assessing risk of a tauopathy in a person comprising:
collecting a nasal sample of exhaled breath from the person's nose using a nasal breath collection device;
analyzing the nasal sample to detect a presence and measure a concentration of tau protein in the nasal sample of exhaled breath from the person's nose;
collecting a mouth sample of exhaled breath from a person's mouth using a collection device;
analyzing the mouth sample to detect a presence and a concentration of tau protein in the mouth sample of exhaled breath from a person's mouth;
determining a difference between the concentration of tau protein in the nasal sample of exhaled breath from the person's nose and the concentration of tau protein in the mouth sample of exhaled breath from the person's mouth,
wherein the difference indicates susceptibility to Alzheimer's disease or dementia.
8. The method of claim 7 , wherein the nasal sample and mouth sample are analyzed using an ELISA assay.
9. The method of claim 7 , wherein the nasal sample and mouth sample are analyzed using a Simoa Human Total Tau assay.
10. The method of claim 7 , wherein the nasal sample and the mouth sample are analyzed using a gas-chromatographic technique.
11. The method of claim 10 , wherein the gas-chromatographic technique is combined with mass spectrometry.